The Prime Minister’s Office in a press release on Saturday (October 17) mentioned that two pan-India research on the genome of the coronavirus recommend it’s genetically steady and has proven no main mutation in India.
The PMO mentioned, “Two pan-India studies on the Genome of SARS-CoV-2 (COVID-19 virus) in India conducted by ICMR and the Department of Biotechnology (DBT) suggest that the virus is genetically stable and there is no major mutation in the virus.”
Mutation refers back to the property of a virus to endure modifications when it multiplies and the virus might develop some new strains after it replicates. In cases, the new strains are usually much less efficient and due to this fact die out quickly, while extra highly effective strains might result in quicker unfold of the virus.
Earlier it was reported that many consultants had been involved that any main mutation in coronavirus might have an effect on the event of an efficient vaccine. But some latest research have proven that mutations of coronavirus wouldn’t have an effect on the effectiveness of the vaccines.
The PMO issued the assertion shortly after Prime Minister Narendra Modi chaired a high-level assembly on the Covid-19 pandemic scenario, vaccine supply, distribution and administration preparedness.
The Prime Minister’s Office mentioned in a press release that three vaccines are in superior phases of growth in India, out of which two are in Phase II and one is in Phase-III.
Union Health Minister Harsh Vardhan in September had mentioned that no important mutations have been present in strains of SARS-CoV-2 in India until now.
Harsh Vardhan had additionally knowledgeable the media that a large-scale sequencing of nationally consultant strains collected over the previous few weeks is already performed by the Indian Council of Medical Research and the outcomes on mutations of the virus will be obtainable in October.
The PMO assertion additionally mentioned that a National Expert Group on Vaccine Administration for COVID-19 (NEGVAC) has ready an in depth blueprint of vaccine storage, distribution, and administration.
The Expert Group, in session with states, is working actively on prioritisation and distribution of vaccines.